Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals reported strong revenue growth for the half-year ending June 30, 2025, with total revenue reaching $390.4 million, marking a 63% increase from the previous year. Despite the revenue growth, the company recorded an operating loss of $2.3 million due to increased finance costs and investments in research and development. Telix is positioning itself for long-term growth by expanding its product line and geographic reach, notably through the acquisition of RLS Radiopharmacies and the pending approvals of new products.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products. The company is expanding its business operations and investing in research and development to support the launch of new products and enter new markets.
Average Trading Volume: 1,771,469
Technical Sentiment Signal: Sell
Current Market Cap: A$6B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.